Journal of International Oncology ›› 2023, Vol. 50 ›› Issue (3): 157-163.doi: 10.3760/cma.j.cn371439-20221123-00031
• Original Articles • Previous Articles Next Articles
Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun()
Received:
2022-11-23
Revised:
2023-01-16
Online:
2023-03-08
Published:
2023-04-12
Contact:
Chen Yongshun, Email: Supported by:
Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun. Construction of postoperative prognosis model for patients with colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 157-163.
"
临床病理特征 | 例数 | SIS 0分组(n=70) | SIS 1分组(n=172) | SIS 2分组(n=108) | χ2值 | P值 |
---|---|---|---|---|---|---|
年龄(岁) | ||||||
>60 | 205 | 36(51.43) | 87(50.58) | 82(75.93) | 19.40 | <0.001 |
≤60 | 145 | 34(48.57) | 85(49.42) | 26(24.07) | ||
性别 | ||||||
男 | 215 | 35(50.00) | 108(62.79) | 72(66.67) | 5.24 | 0.073 |
女 | 135 | 35(50.00) | 64(37.21) | 36(33.33) | ||
肿瘤部位 | ||||||
直肠 | 187 | 34(48.57) | 105(61.05) | 48(44.44) | 8.18 | 0.017 |
结肠 | 163 | 36(51.43) | 67(38.95) | 60(55.56) | ||
临床病理特征 | 例数 | SIS 0分组(n=70) | SIS 1分组(n=172) | SIS 2分组(n=108) | χ2值 | P值 |
T分期 | ||||||
T1 | 19 | 7(10.00) | 8(4.65) | 4(3.70) | 10.01 | 0.007 |
T2 | 67 | 25(35.71) | 34(19.77) | 8(7.40) | ||
T3 | 138 | 12(17.14) | 75(43.60) | 51(47.22) | ||
T4 | 126 | 26(37.14) | 55(31.98) | 45(41.67) | ||
N分期 | ||||||
N0 | 175 | 43(61.43) | 79(45.93) | 53(49.07) | 4.52 | 0.104 |
N1 | 127 | 19(27.14) | 65(37.79) | 43(39.81) | ||
N2 | 48 | 8(11.43) | 28(76.28) | 12(11.11) | ||
TNM分期 | ||||||
Ⅰ | 62 | 25(35.71) | 31(18.02) | 6(5.56) | 14.80 | 0.001 |
Ⅱ | 109 | 18(25.71) | 48(27.91) | 43(39.81) | ||
Ⅲ | 160 | 26(37.14) | 86(50.00) | 48(44.44) | ||
Ⅳ | 19 | 1(1.43) | 7(4.07) | 11(10.19) | ||
肿瘤直径(cm) | ||||||
>4.5 | 125 | 20(28.57) | 51(29.65) | 54(50.00) | 13.91 | 0.001 |
≤4.5 | 225 | 50(71.43) | 121(70.35) | 54(50.00) | ||
神经侵犯 | ||||||
是 | 108 | 18(25.71) | 53(30.81) | 37(34.26) | 1.45 | 0.483 |
否 | 242 | 52(74.29) | 119(69.19) | 71(65.74) | ||
脉管侵袭 | ||||||
是 | 118 | 17(24.29) | 64(37.21) | 37(34.26) | 3.74 | 0.154 |
否 | 232 | 53(75.71) | 108(62.79) | 71(65.74) | ||
CEA(ng/ml) | ||||||
>5 | 99 | 12(17.14) | 44(25.58) | 43(39.81) | 10.12 | 0.006 |
≤5 | 230 | 51(72.86) | 117(68.02) | 62(57.41) | ||
未知 | 21 | 7(10.00) | 11(6.40) | 3(2.78) | ||
注:CRC为结直肠癌;SIS为全身炎症评分;CEA为癌胚抗原 |
"
因素 | 单因素分析 | 多因素分析 | |||||
---|---|---|---|---|---|---|---|
HR值 | 95%CI | P值 | HR值 | 95%CI | P值 | ||
年龄(>60岁/≤60岁) | 2.58 | 1.54~4.32 | <0.001 | 2.27 | 1.31~3.91 | 0.003 | |
性别(男/女) | 0.97 | 0.62~1.51 | 0.878 | ||||
肿瘤部位(结肠/直肠) | 1.08 | 0.70~1.68 | 0.719 | ||||
T分期(T3-4/T1-2) | 2.41 | 1.24~4.68 | 0.009 | 1.03 | 0.51~2.10 | 0.928 | |
N分期(N1-2/N0) | 3.03 | 1.85~4.94 | <0.001 | 0.38 | 0.11~1.35 | 0.134 | |
TNM分期(Ⅲ~Ⅳ/Ⅰ~Ⅱ) | 3.61 | 2.15~6.04 | <0.001 | 7.08 | 1.89~26.59 | 0.004 | |
肿瘤直径(>4.5 cm/≤4.5 cm) | 1.26 | 0.81~1.97 | 0.313 | ||||
神经侵犯(是/否) | 1.97 | 1.27~3.08 | 0.002 | 1.23 | 0.76~1.99 | 0.410 | |
脉管侵袭(是/否) | 2.31 | 1.49~3.59 | <0.001 | 1.52 | 0.95~2.42 | 0.079 | |
术前SIS(1分/0分) | 5.09 | 1.57~16.56 | 0.007 | 2.97 | 0.86~10.34 | 0.086 | |
术前SIS(2分/0分) | 11.05 | 3.42~35.65 | <0.001 | 4.02 | 1.09~14.83 | 0.037 | |
术前NLR(>3.10/≤3.10) | 2.97 | 1.90~4.64 | <0.001 | 1.43 | 0.81~2.52 | 0.223 | |
术前LMR(>3.68/≤3.68) | 0.31 | 0.19~0.52 | <0.001 | 0.65 | 0.36~1.17 | 0.148 | |
术前SII(>470.23/≤470.23) | 2.50 | 1.54~4.06 | <0.001 | 1.23 | 0.67~2.25 | 0.499 |
[1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
doi: 10.3322/caac.21660 |
[2] |
Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5): 584-590. DOI: 10.1097/CM9.0000000000002108.
doi: 10.1097/CM9.0000000000002108 |
[3] |
Salimzadeh H, Lindskog EB, Gustavsson B, et al. Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival[J]. BMC Cancer, 2020, 20(1): 409. DOI: 10.1186/s12885-020-06924-z.
doi: 10.1186/s12885-020-06924-z pmid: 32397974 |
[4] |
Chan JCY, Diakos CI, Chan DLH, et al. A longitudinal investigation of inflammatory markers in colorectal cancer patients perioperatively demonstrates benefit in serial remeasurement[J]. Ann Surg, 2018, 267(6): 1119-1125. DOI: 10.1097/SLA.0000000000002251.
doi: 10.1097/SLA.0000000000002251 pmid: 28394869 |
[5] |
Dolan RD, McSorley ST, Park JH, et al. The prognostic value of systemic inflammation in patients undergoing surgery for colon cancer: comparison of composite ratios and cumulative scores[J]. Br J Cancer, 2018, 119(1): 40-51. DOI: 10.1038/s41416-018-0095-9.
doi: 10.1038/s41416-018-0095-9 |
[6] |
Chen JH, Zhai ET, Yuan YJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer[J]. World J Gastroenterol, 2017, 23(34): 6261-6272. DOI: 10.3748/wjg.v23.i34.6261.
doi: 10.3748/wjg.v23.i34.6261 |
[7] |
Verter E, Berger Y, Perl G, et al. Neutrophil-to-lymphocyte ratio predicts recurrence pattern in patients with resectable colorectal liver metastases[J]. Ann Surg Oncol, 2021, 28(8): 4320-4329. DOI: 10.1245/s10434-021-10000-6.
doi: 10.1245/s10434-021-10000-6 |
[8] |
Thanikachalam K, Khan G. Colorectal cancer and nutrition[J]. Nutrients, 2019, 11(1): 164. DOI: 10.3390/nu11010164.
doi: 10.3390/nu11010164 |
[9] |
Yamamoto T, Kawada K, Obama K. Inflammation-related biomar-kers for the prediction of prognosis in colorectal cancer patients[J]. Int J Mol Sci, 2021, 22(15): 8002. DOI: 10.3390/ijms22158002.
doi: 10.3390/ijms22158002 |
[10] |
Tian G, Li G, Guan L, et al. Pretreatment albumin-to-alkaline phosphatase ratio as a prognostic indicator in solid cancers: a meta-analysis with trial sequential analysis[J]. Int J Surg, 2020, 81: 66-73. DOI: 10.1016/j.ijsu.2020.07.024.
doi: S1743-9191(20)30559-8 pmid: 32745716 |
[11] |
An L, Yin WT, Sun DW. Albumin-to-alkaline phosphatase ratio as a promising indicator of prognosis in human cancers: is it possible?[J]. BMC Cancer, 2021, 21(1): 247. DOI: 10.1186/s12885-021-07921-6.
doi: 10.1186/s12885-021-07921-6 pmid: 33685425 |
[12] |
Wang F, He W, Jiang C, et al. Prognostic value of inflammation-based scores in patients receiving radical resection for colorectal cancer[J]. BMC Cancer, 2018, 18(1): 1102. DOI: 10.1186/s12885-018-4842-3.
doi: 10.1186/s12885-018-4842-3 pmid: 30419863 |
[13] |
Cassetta L, Fragkogianni S, Sims AH, et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets[J]. Cancer Cell, 2019, 35(4): 588-602, e10. DOI: 10.1016/j.ccell.2019.02.009.
doi: S1535-6108(19)30104-7 pmid: 30930117 |
[14] |
Kemp SB, Steele NG, Carpenter ES, et al. Pancreatic cancer is marked by complement-high blood monocytes and tumor-associated macrophages[J]. Life Sci Alliance, 2021, 4(6): e202000935. DOI: 10.26508/lsa.202000935.
doi: 10.26508/lsa.202000935 |
[15] |
Sasaki A, Kai S, Endo Y, et al. Prognostic value of preoperative peripheral blood monocyte count in patients with colorectal liver metastasis after liver resection[J]. J Gastrointest Surg, 2007, 11(5): 596-602. DOI: 10.1007/s11605-007-0140-0.
doi: 10.1007/s11605-007-0140-0 pmid: 17468918 |
[16] |
Chan JC, Chan DL, Diakos CI, et al. The lymphocyte-to-monocyte ratio is a superior predictor of overall survival in comparison to established biomarkers of resectable colorectal cancer[J]. Ann Surg, 2017, 265(3): 539-546. DOI: 10.1097/SLA.0000000000001743.
doi: 10.1097/SLA.0000000000001743 pmid: 27070934 |
[17] |
Li Y, Jia H, Yu W, et al. Nomograms for predicting prognostic value of inflammatory biomarkers in colorectal cancer patients after radical resection[J]. Int J Cancer, 2016, 139(1): 220-231. DOI: 10.1002/ijc.30071.
doi: 10.1002/ijc.30071 pmid: 26933932 |
[18] |
Suzuki Y, Okabayashi K, Hasegawa H, et al. Comparison of preoperative inflammation-based prognostic scores in patients with colorectal cancer[J]. Ann Surg, 2018, 267(3): 527-531. DOI: 10.1097/SLA.0000000000002115.
doi: 10.1097/SLA.0000000000002115 pmid: 27984214 |
[1] | Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma: a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331. |
[2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[3] | Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375. |
[4] | Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381. |
[5] | Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266. |
[6] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[7] | Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285. |
[8] | Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197. |
[9] | Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209. |
[10] | Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222. |
[11] | Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150. |
[12] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180. |
[13] | Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185. |
[14] | Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118. |
[15] | Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||